心血管-肾脏-代谢综合征的诊治新进展

doi:10.3969/j.issn.1004-583X.2025.10.012

摘要/Abstract

摘要：

心血管-肾脏-代谢综合征(cardiovascular-kidney-metabolic syndrome, CKMS)是指肥胖、2型糖尿病、慢性肾脏疾病和心血管疾病间因病理、生理相互作用而引发的全身性疾病,近年来备受关注。本文对CKMS的流行病学、危险因素、发病机制及治疗进展进行了全面阐述,旨在为临床实践和进一步研究提供参考。

中图分类号:

陈家男, 罗群, 蔡珂丹. 心血管-肾脏-代谢综合征的诊治新进展[J]. 临床荟萃, 2025, 40(10): 948-953.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.10.012

https://www.lchc.cn/CN/Y2025/V40/I10/948

参考文献 63

[1]	Sun P, Ming X, Song T, et al. Global burden of chronic kidney disease in adolescents and young adults, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Front Endocrinol (Lausanne), 2024, 15: 1389342.doi:10.3389/fendo.2024.1389342.
[2]	Chen Q, Huang S, Wang X, et al. The burden of diseases attributable to high body mass index in Asia from 1990-2019: Results from the global burden of disease study 2019[J]. Ann Med, 2025, 57(1): 2483977.doi:10.1080/07853890.2025.2483977.
[3]	Barry A, Impouma B, Wolfe CM, et al. Non-communicable diseases in the WHO African region: Analysis of risk factors, mortality, and responses based on WHO data[J]. Sci Rep, 2025, 15(1): 12288.doi:10.1038/s41598-025-97180-3.
[4]	Roppelt JS, Kanbach DK, Kraus S. Artificial intelligence in healthcare institutions: A systematic literature review on influencing factors[J]. Technol Soc, 2024, 76: 102443.doi:10.1016/j.techsoc.2023.102443.
[5]	Thomas SA, Browning CJ, Charchar FJ, et al. Transforming global approaches to chronic disease prevention and management across the lifespan: Integrating genomics, behavior change, and digital health solutions[J]. Front Public Health, 2023, 11: 1248254.doi:10.3389/fpubh.2023.1248254.
[6]	Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association[J]. Circulation, 2023, 148(20): 1606-1635.doi:10.1161/cir.0000000000001184. pmid: 37807924
[7]	Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020[J]. Jama, 2024, 331(21): 1858-1860.doi:10.1001/jama.2024.6892. pmid: 38717747
[8]	Minhas AMK, Mathew RO, Sperling LS, et al. Prevalence of the cardiovascular-kidney-metabolic syndrome in the United States[J]. J Am Coll Cardiol, 2024, 83(18): 1824-1826.doi:10.1016/j.jacc.2024.03.368.
[9]	Ji H, Sabanayagam C, Matsushita K, et al. Sex differences in cardiovascular-kidney-metabolic syndrome: 30-year US trends and mortality risks-brief report[J]. Arterioscler Thromb Vasc Biol, 2025, 45(1): 157-161.doi:10.1161/atvbaha.124.321629. pmid: 39665141
[10]	Huang Q, Li Y, Zhou X, et al. Prevalence of the cardiovascular-kidney-metabolic syndrome in 3 Chinese cohorts[J]. JACC Asia, 2025, 5(1): 116-118.doi:10.1016/j.jacasi.2024.10.016. pmid: 39886203
[11]	Sumi S, Ramachandran S, Ramankutty V, et al. ENPP1 121Q functional variant enhances susceptibility to coronary artery disease in South Indian patients with type 2 diabetes mellitus[J]. Mol Cell Biochem, 2017, 435(1-2): 67-72.doi:10.1007/s11010-017-3057-2. pmid: 28497367
[12]	Bakshi A, Jefferis J, Wolfe R, et al. Association of polygenic scores with chronic kidney disease phenotypes in a longitudinal study of older adults[J]. Kidney Int, 2023, 103(6): 1156-1166.doi:10.1016/j.kint.2023.03.017. pmid: 37001602
[13]	Babicki M, Kłoda K, Ledwoch J, et al. The impact of lifestyle, measured with the HLPCQ questionnaire on the prevalence of metabolic syndrome in Poland: A multicenter study[J]. Sci Rep, 2024, 14(1): 10070.doi:10.1038/s41598-024-60866-1. pmid: 38698159
[14]	Powell-Wiley TM, Baumer Y, Baah FO, et al. Social determinants of cardiovascular disease[J]. Circ Res, 2022, 130(5): 782-799.doi:10.1161/circresaha.121.319811. pmid: 35239404
[15]	Zhu R, Wang R, He J, et al. Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health[J]. JAMA Netw Open, 2024, 7(11): e2445309.doi:10.1001/jamanetworkopen.2024.45309.
[16]	Zhang Y, Kuang J, Xin Z, et al. Loneliness, social isolation, depression and anxiety among the elderly in Shanghai: Findings from a longitudinal study[J]. Arch Gerontol Geriatr, 2023, 110: 104980.doi:10.1016/j.archger.2023.104980.
[17]	Huang X, Liang J, Zhang J, et al. Association of cardiovascular-kidney-metabolic health and social connection with the risk of depression and anxiety[J]. Psychol Med, 2024, 54(15): 1-9.doi:10.1017/s0033291724002381.
[18]	Khraishah H, Alahmad B, Ostergard RL Jr, et al. Climate change and cardiovascular disease: Implications for global health[J]. Nat Rev Cardiol, 2022, 19(12): 798-812.doi:10.1038/s41569-022-00720-x. pmid: 35672485
[19]	Fu P, Guo X, Cheung FMH, et al. The association between PM(2.5) exposure and neurological disorders: A systematic review and meta-analysis[J]. Sci Total Environ, 2019, 655: 1240-1248.doi:10.1016/j.scitotenv.2018.11.218.
[20]	Khraishah H, Rajagopalan S. Inhaling poor health: The impact of air pollution on cardiovascular kidney metabolic syndrome[J]. Methodist Debakey Cardiovasc J, 2024, 20(5): 47-58.doi:10.14797/mdcvj.1487. pmid: 39525378
[21]	Reiner Ž, Jelakovi'c B, Miliˇci'c D, et al. Effective strategies and a ten-point plan for cardio-kidney-metabolic health in Croatia: An expert opinion[J]. J Clin Med, 2024, 13(23) doi:10.3390/jcm13237028.
[22]	Shah AS, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: A systematic review and meta-analysis[J]. Lancet, 2013, 382(9897): 1039-1048.doi:10.1016/s0140-6736(13)60898-3. pmid: 23849322
[23]	Liu J, Liu C, Liu Z, et al. Spatial analysis of air pollutant exposure and its association with metabolic diseases using machine learning[J]. BMC Public Health, 2025, 25(1): 831.doi:10.1186/s12889-025-22077-9. pmid: 40025455
[24]	Kipp ZA, Badmus OO, Stec DE, et al. Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the cardiovascular-kidney-metabolic (CKM) syndrome[J]. Metabolism, 2025, 163: 156081.doi:10.1016/j.metabol.2024.156081.
[25]	Schleh MW, Caslin HL, Garcia JN, et al. Metaflammation in obesity and its therapeutic targeting[J]. Sci Transl Med, 2023, 15(723): eadf9382.doi:10.1126/scitranslmed.adf9382.
[26]	Martínez Báez A, Ayala G, Pedroza-Saavedra A, et al. Phosphorylation codes in IRS-1 and IRS-2 are associated with the activation/inhibition of insulin canonical signaling pathways[J]. Curr Issues Mol Biol, 2024, 46(1): 634-649.doi:10.3390/cimb46010041. pmid: 38248343
[27]	Liu Y, Wang D, Jin Y, et al. Costunolide ameliorates angiotensin II-induced atrial inflammation and fibrosis by regulating mitochondrial function and oxidative stress in mice: A possible therapeutic approach for atrial fibrillation[J]. Microvasc Res, 2024, 151: 104600.doi:10.1016/j.mvr.2023.104600.
[28]	Caputo I, Bertoldi G, Driussi G, et al. The RAAS goodfellas in cardiovascular system[J]. J Clin Med, 2023, 12(21): 6873.doi:10.3390/jcm12216873.
[29]	Sebastian SA, Padda I, Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review[J]. Curr Probl Cardiol, 2024, 49(2): 102344.doi:10.1016/j.cpcardiol.2023.102344.
[30]	Massy ZA, Drueke TB. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations[J]. Kidney Int Rep, 2024, 9(9): 2608-2618.doi:10.1016/j.ekir.2024.05.033. pmid: 39291205
[31]	Muttiah B, Hanafiah A. Gut microbiota and cardiovascular diseases: Unraveling the role of dysbiosis and microbial metabolites[J]. Int J Mol Sci, 2025, 26(9). doi:10.3390/ijms26094264.
[32]	Chao CT, Lin SH. Uremic toxins and frailty in patients with chronic kidney disease: A molecular insight[J]. Int J Mol Sci, 2021, 22(12): 6270.doi:10.3390/ijms22126270.
[33]	Chen W, Li ML, Zeng G, et al. Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic disease[J]. Pharmacol Res, 2025: 107794.doi:10.1016/j.phrs.2025.107794.
[34]	Nemet I, Saha PP, Gupta N, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors[J]. Cell, 2020, 180(5): 862-877.e822.doi:10.1016/j.cell.2020.02.016. pmid: 32142679
[35]	Li W, He P, Huang Y, et al. Selective autophagy of intracellular organelles:Recent research advances[J]. Theranostics, 2021, 11(1): 222-256.doi:10.7150/thno.49860.
[36]	Nguyen K, Tang J, Cho S, et al. Salubrinal promotes phospho-eIF2α-dependent activation of UPR leading to autophagy-mediated attenuation of iron-induced insulin resistance[J]. Mol Metab, 2024, 83: 101921.doi:10.1016/j.molmet.2024.101921.
[37]	Chung J, Park J, Lai ZW, et al. The Troyer syndrome protein spartin mediates selective autophagy of lipid droplets[J]. Nat Cell Biol, 2023, 25(8): 1101-1110.doi:10.1038/s41556-023-01178-w. pmid: 37443287
[38]	Wang J, Guo Y, Hu J, et al. STING activation in various cell types in metabolic dysfunction-associated ateatotic liver disease[J]. Liver Int, 2025, 45(4): e70063.doi:10.1111/liv.70063.
[39]	Lu C, Zhang Y, Sun C, et al. Stromal cell derived factor-1 promotes hepatic insulin resistance via inhibiting hepatocyte lipophagy[J]. J Cell Mol Med, 2025, 29(2): e70352.doi:10.1111/jcmm.70352.
[40]	Chen W, Jin T, Xie Y, et al. Berberine partially ameliorates cardiolipotoxicity in diabetic cardiomyopathy by modulating SIRT3-mediated lipophagy to remodel lipid droplets homeostasis[J]. Br J Pharmacol, 2025, 182(20): 5038-5056.doi:10.1111/bph.70035.
[41]	Yamashita SI, Sugiura Y, Matsuoka Y, et al. Mitophagy mediated by BNIP3 and NIX protects against ferroptosis by downregulating mitochondrial reactive oxygen species[J]. Cell Death Differ, 2024, 31(5): 651-661.doi:10.1038/s41418-024-01280-y.
[42]	Lefort KR, Rungratanawanich W, Song BJ. Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction[J]. Cell Mol Life Sci, 2024, 81(1): 34.doi:10.1007/s00018-023-05061-7. pmid: 38214802
[43]	Pliouta L, Lampsas S, Kountouri A, et al. Mitochondrial dysfunction in the development and progression of cardiometabolic diseases: A narrative review[J]. J Clin Med, 2025, 14(11): 3706.doi: 10.3390/jcm14113706.
[44]	Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association[J]. Circulation, 2023, 148(20): 1636-1664.doi:10.1161/cir.0000000000001186. pmid: 37807920
[45]	Kazory A, Mccullough PA, Rangaswami J, et al. Cardionephrology: Proposal for a futuristic educational approach to a contemporary need[J]. Cardiorenal Med, 2018, 8(4): 296-301.doi:10.1159/000490744. pmid: 30089281
[46]	Krist AH, Davidson KW, Mangione CM, et al. Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement[J]. JAMA, 2021, 325(16): 1650-1656.doi:10.1001/jama.2021.4987. pmid: 33904861
[47]	O'brien MJ, Zhang Y, Bailey SC, et al. Screening for prediabetes and diabetes: Clinical performance and implications for health equity[J]. Am J Prev Med, 2023, 64(6): 814-823.doi:10.1016/j.amepre.2023.01.007. pmid: 37171231
[48]	Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11): 825-830.doi:10.7326/0003-4819-158-11-201306040-00007. pmid: 23732715
[49]	Page KA, Luo S, Wang X, et al. Children exposed to maternal obesity or gestational diabetes mellitus during early fetal development have hypothalamic alterations that predict future weight gain[J]. Diabetes Care, 2019, 42(8): 1473-1480.doi:10.2337/dc18-2581. pmid: 31332028
[50]	Liu Z, Gao P, Gao AY, et al. Effectiveness of a multifaceted intervention for prevention of obesity in primary school children in China: A cluster randomized clinical trial[J]. JAMA Pediatr, 2022, 176(1): e214375.doi:10.1001/jamapediatrics.2021.4375.
[51]	Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease[J]. Arch Intern Med, 1999, 159(10): 1104-1109.doi:10.1001/archinte.159.10.1104. pmid: 10335688
[52]	Lloyd-Jones DM, Liu K, Colangelo LA, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: The coronary artery risk development in young adults study[J]. Circulation, 2007, 115(8): 1004-1011.doi:10.1161/circulationaha.106.648642. pmid: 17283263
[53]	Kim HL, Chung J, Kim KJ, et al. Lifestyle modification in the management of metabolic syndrome: Statement from Korean Society of CardioMetabolic Syndrome (KSCMS)[J]. Korean Circ J, 2022, 52(2): 93-109.doi:10.4070/kcj.2021.0328.
[54]	Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials[J]. Lancet, 2003, 361(9374): 2017-2023.doi:10.1016/s0140-6736(03)13637-9. pmid: 12814711
[55]	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: Executive Summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019, 74(10): 1376-1414.doi:10.1016/j.jacc.2019.03.009. pmid: 30894319
[56]	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2019, 140(11): e596-e646.doi:10.1161/cir.0000000000000678.
[57]	Lavie CJ, Ozemek C, Carbone S, et al. Sedentary behavior, exercise, and cardiovascular health[J]. Circ Res, 2019, 124(5): 799-815.doi:10.1161/circresaha.118.312669. pmid: 30817262
[58]	Armstrong MJ, Mottershead TA, Ronksley PE, et al. Motivational interviewing to improve weight loss in overweight and/or obese patients: A systematic review and meta-analysis of randomized controlled trials[J]. Obes Rev, 2011, 12(9): 709-723.doi:10.1111/j.1467-789X.2011.00892.x. pmid: 21692966
[59]	Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3): 205-216.doi:10.1056/NEJMoa2206038.
[60]	Elsayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023[J]. Diabetes Care, 2023, 46(Suppl 1): S140-s157.doi:10.2337/dc23-S009.
[61]	Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur J Prev Cardiol, 2021, 29(1): 5-115.doi:10.1093/eurjpc/zwab154. pmid: 34558602
[62]	Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med, 2019, 380(1): 11-22.doi:10.1056/NEJMoa1812792.
[63]	González-Juanatey JR, Górriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: Protecting kidney and heart[J]. Ann Med, 2023, 55(1): 502-513.doi:10.1080/07853890.2023.2171110. pmid: 36719097

心血管-肾脏-代谢综合征的诊治新进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 63

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦婷婷, 潘正燕, 冯鲜燕, 龙亚秀. 基于SEER数据库的结直肠癌肝转移危险因素分析:倾向评分匹配研究[J]. 临床荟萃, 2025, 40(9): 816-820.
[2]	马良, Severine Martin, 孙广东. 基于加蓬数据的疟疾相关急性肾损伤患者临床特征分析[J]. 临床荟萃, 2025, 40(8): 717-720.
[3]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.
[4]	何媛, 王俭. 特发性脊柱侧凸患者神经与结构影像相关改变的研究进展[J]. 临床荟萃, 2025, 40(7): 669-672.
[5]	王思晗, 李向红, 李亮亮, 锡洪敏, 杨萍, 马丽丽, 尹向云. 新生儿RYR1相关肌病1例并文献复习[J]. 临床荟萃, 2025, 40(6): 541-546.
[6]	肇雪婷, 白佳雯, 孙军. 代谢相关脂肪性肝病肝纤维化危险因素分析及构建预测模型[J]. 临床荟萃, 2025, 40(5): 417-422.
[7]	肖珂, 王奇. 2型糖尿病伴隐球菌性脑膜炎患者的临床特征及危险因素分析[J]. 临床荟萃, 2025, 40(5): 423-427.
[8]	田晓婷, 卢泽芬. 肺癌患者静脉血栓栓塞危险因素的研究进展[J]. 临床荟萃, 2025, 40(5): 473-476.
[9]	许慧峰, 晋艳勇, 苟若澜, 胡明哲. 脑出血患儿并发脑积水的危险因素及预测模型[J]. 临床荟萃, 2025, 40(4): 325-328.
[10]	童明霞, 陈柯, 向小聪, 周丽峰. 中青年体检人群瘦型代谢相关脂肪性肝病及其危险因素分析[J]. 临床荟萃, 2025, 40(2): 128-132.
[11]	钱晨莹, 闫文君, 黄燕, 赵志. 肝硬化失代偿期患者合并多重耐药菌感染的危险因素分析[J]. 临床荟萃, 2025, 40(2): 143-146.
[12]	温甜甜, 魏星, 马苗苗, 马丽群. 阻塞性睡眠呼吸暂停诱导残余胆固醇升高与冠心病机制及研究进展[J]. 临床荟萃, 2025, 40(11): 1035-1042.
[13]	刘胜华. 游离甲状腺素联合左室射血分数对甲亢性心脏病的评估价值[J]. 临床荟萃, 2025, 40(10): 897-903.
[14]	蒲茜, 成刚, 道杰草, 齐梓兆, 窦乐乐, 赵军芳, 张文君, 郭彩霞, 王莹莹. 甘肃地区单中心慢性肾脏病患者便秘患病率及危险因素分析[J]. 临床荟萃, 2025, 40(1): 44-53.
[15]	赵一品, 崔清洋. 超早产儿/超低出生体重儿支气管肺发育不良危险因素分析[J]. 临床荟萃, 2025, 40(1): 60-64.